Grants for Public housing authorities - Health

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels.The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use.Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

This funding opportunity supports innovative research on how substance use disorders affect HIV infection and latency in the brain, encouraging collaboration among researchers in HIV, neuroscience, and addiction.

This grant provides funding for research on how climate change affects cancer risks, prevention, treatment, and survivorship, particularly focusing on vulnerable populations and health disparities.

This funding opportunity provides financial support to organizations that will assist Botswana's Ministry of Health in implementing national HIV policies and improving care and mental health services for children and adolescents living with HIV.

This funding opportunity supports collaborative projects between academic institutions and industry to develop innovative bioengineering solutions that address significant biomedical challenges and improve medical practices.

The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) works to ensure patient safety in multiple settings with recent efforts to increase the development of processes including measures, metrics, tools and practices to increase patient safety in the ambulatory care setting and in long-term care facilities.

This funding supports institutions in developing training programs for predoctoral and postdoctoral researchers in biomedical and clinical fields, with a focus on enhancing diversity and preparing trainees for successful research careers.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations.

This funding opportunity supports researchers in developing innovative strategies to eliminate HIV proteins by targeting viral RNA or proteins for degradation, with a focus on advancing new therapeutic approaches.

This funding opportunity supports research projects aimed at developing and planning clinical trials that integrate effective HIV prevention strategies for populations affected by alcohol use, focusing on reducing new HIV infections.

This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field;apos;s ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.

This grant provides funding for researchers to conduct multi-site clinical trials focused on effective treatments and preventive interventions for health issues related to aging, specifically targeting older adults with complex health conditions.

This funding opportunity provides financial support for organizations to develop and implement innovative strategies for tuberculosis prevention and detection in high-burden countries, focusing on treatment optimization and improved case finding.

This funding opportunity provides financial support to early-career researchers from diverse backgrounds to develop innovative cancer research projects and enhance workforce diversity in the field.

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and methods of interest will test outcomes and mechanisms of action in settings customized for individuals with different needs and linked to real-world function. Applications must explain how the platform will meet evolving community needs and partner with other NIA-funded programs. Applications must also describe activities that will achieve the following objectives: Develop an organizational and governance structure to support the administration, innovation, and dissemination functions of the Network. Propose activities to establish a framework that will facilitate the development of innovative strategies for standardization and use of methods and measures across NIA-supported projects and support activities for the discovery and development of innovative and novel measures and data. Disseminate Network resources and products to the broader AD/ADRD research community. Ensure that all measures and methods development and validation occurs in a racially, ethnically, geographically, and diagnostically diverse set of participants, including members of NIH-defined Health Disparity Populations. This also includes establishing the acceptability and feasibility of using the proposed instruments in both cognitively normal individuals and persons living with cognitive impairment (PLWCI), including subjective cognitive decline. NIA is particularly interested in proposals that advance equity for populations disproportionately impacted by AD/ADRD. For example, Black and Hispanic Americans have a higher prevalence of AD/ADRD compared to non-Hispanic White Americans. Resources, including measurement instruments, methods, algorithms, code, documentation, and normative data will enable other, future measures and methods development projects that support AD/ADRD primary prevention research needs. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early 2024 with an expected application due date in Spring/Summer 2024. This NOFO will utilize the U24 activity code.

The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity supports research projects aimed at improving cancer care and outcomes for sexual and gender minority survivors by addressing healthcare disparities and enhancing access to quality treatment.

This funding opportunity provides financial support for organizations to evaluate and implement overdose prevention strategies targeting communities disproportionately affected by substance use disorders and overdose deaths.

This funding opportunity supports interdisciplinary research teams to explore how medical devices can effectively relieve chronic pain while minimizing addiction risks.

This funding opportunity provides additional financial support to active health services research projects facing unforeseen costs, helping researchers continue their work effectively.